These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38633010)

  • 1. The Effect of Vaccination with Pfizer-BioNTech or CoronaVac on Disease Prognosis Among Hospitalized COVID-19 Patients.
    Güldan M; Ateş ST; Sarıoğlu S; Suyabatmaz S; İrkören P; Tekin S; Kapmaz M; Keske Ş; Ergönül Ö
    Infect Dis Clin Microbiol; 2023 Jun; 5(2):106-112. PubMed ID: 38633010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers].
    Çiçek K; Özkaya Y; Eser E; Buran ZC; Öztürk Arıkan ZÖ; Akçalı S; Erbay Dündar P; Cengiz Özyurt B; Şenol Akar Ş; Özer D; Karadağ Yalçın F
    Mikrobiyol Bul; 2023 Apr; 57(2):238-251. PubMed ID: 37067208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
    Yürüker Ö; Yetkin O; Güvenir M
    Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19.
    Dogan M; Yilmaz B
    Acta Pharm; 2023 Jun; 73(2):257-268. PubMed ID: 37307370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of clinical outcomes of vaccinated and unvaccinated patients with hospitalization for COVID-19.
    Ozdemir YE; Kizilcay B; Sonmezisik M; Tarhan MS; Borcak D; Sahin Ozdemir M; Bayramlar OF; Yesilbag Z; Senoglu S; Gedik H; Kumbasar Karaosmanoglu H; Kart Yasar K
    Acta Microbiol Immunol Hung; 2022 Dec; 69(4):270-276. PubMed ID: 36129790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of CoronaVac (Sinovac) and BNT162b2 (BioNTech/Pfizer) Vaccination on Oncologic
    Şan H; Alagöz E
    Mol Imaging Radionucl Ther; 2022 Oct; 31(3):179-190. PubMed ID: 36268854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile.
    Díaz-Dinamarca DA; Díaz P; Barra G; Puentes R; Arata L; Grossolli J; Riveros-Rodriguez B; Ardiles L; Santelises J; Vasquez-Saez V; Escobar DF; Soto D; Canales C; Díaz J; Lamperti L; Castillo D; Urra M; Zuñiga F; Ormazabal V; Nova-Lamperti E; Benítez R; Rivera A; Cortes CP; Valenzuela MT; García-Escorza HE; Vasquez AE
    Front Public Health; 2023; 11():1229045. PubMed ID: 37693706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
    Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
    Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
    Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E
    J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination.
    Abdul-Wahab Kadhum A; Rushdi Abdullah A; Mujahid A
    Arch Razi Inst; 2023 Jun; 78(3):1071-1075. PubMed ID: 38028836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine.
    Ozdede A; Guner S; Ozcifci G; Yurttas B; Toker Dincer Z; Atli Z; Uygunoğlu U; Durmaz E; Uçar D; Uğurlu S; Saip S; Tabak F; Hamuryudan V; Seyahi E
    Rheumatol Int; 2022 Jun; 42(6):973-987. PubMed ID: 35376962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome.
    Ozdede A; Nohut OK; Atli Z; Tok YT; Guner S; Yilmaz E; Ucar D; Uygunoglu U; Hamuryudan V; Seyahi E
    Rheumatol Int; 2022 Oct; 42(10):1741-1750. PubMed ID: 35779083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses to COVID-19 vaccines in older adults.
    Bag Soytas R; Cengiz M; Islamoglu MS; Borku Uysal B; Yavuzer S; Yavuzer H
    J Med Virol; 2022 Apr; 94(4):1650-1654. PubMed ID: 34921432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer.
    Simsek M; Yasin AI; Besiroglu M; Topcu A; Sucuoglu Isleyen Z; Seker M; Turk HM
    J Med Virol; 2022 Sep; 94(9):4138-4143. PubMed ID: 35513241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Sinovac-Coronavac and Pfizer-BioNTech mRNA vaccines on choroidal and retinal vascular system.
    Sarıtaş Ö; Yorgun MA; Gökpınar E
    Photodiagnosis Photodyn Ther; 2023 Sep; 43():103702. PubMed ID: 37429458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
    Ergun T; Hosgoren Tekin S; Apti Sengun O; Akin Cakici O; Seckin D; Adiay C; Enul H; Yilmaz S; Ay P; Haklar G; Sili U
    Vaccine; 2023 Jun; 41(29):4287-4294. PubMed ID: 37277251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of COVID-19 Vaccines on Hospital Admission and Severity of Symptoms Among COVID-19 Patients in Saudi Arabia, 2021.
    Alnemari RF; Roublah FA; Bargawi AA
    Cureus; 2023 Jun; 15(6):e41067. PubMed ID: 37519611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
    Rosero-Bixby L
    JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.